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Abstract
Background: Pulmonary arterial hypertension (PAH) is a rare disease (15 cases per million) that is characterized by
widespread loss of the pulmonary microcirculation and elevated pulmonary vascular resistance leading to pathological
right ventricular remodeling and ultimately right heart failure. Regenerative cell therapies (i.e., therapies involving cells
with stem or progenitor-like properties) could potentially restore the effective lung microcirculation and provide a
curative therapy for PAH. Preclinical evidence suggests that regenerative cell therapy using endothelial progenitor cells
or mesenchymal stem cells may be beneficial in the treatment of PAH. These findings have led to the completion of a
small number of human clinical trials, albeit with modest effect compared to animal studies. The objective of this
systematic review is to compare the efficacy and safety of regenerative cell therapies in preclinical models of PAH as
well as assess study quality to inform future clinical studies.
Methods: We will include preclinical studies of PAH in which a regenerative cell type was administered and outcomes
compared to a disease control. The primary outcome will be pulmonary hemodynamics as assessed by measurement
of right ventricular systolic pressure and/or mean pulmonary arterial pressure. Secondary outcomes will include
mortality, survival, right ventricular remodeling, pulmonary vascular resistance, cardiac output, cardiac index, pulmonary
acceleration time, tricuspid annular systolic excursion, and right ventricular wall thickness. Electronic searches of
MEDLINE and EMBASE databases will be constructed and reviewed by the Peer Review of Electronic Search Strategies
(PRESS) process. Search results will be screened independently in duplicate. Data from eligible studies will be extracted,
pooled, and analyzed using random effects models. Risk of bias will be assessed using the SYstematic Review Centre
for Laboratory animal Experimentation (SYRCLE) risk of bias tool, and individual study reporting will be assessed
according to an itemized checklist based on the Animal Research: Reporting of In vivo Experiments (ARRIVE) guidelines.
Discussion: This systematic review will examine the efficacy and safety of regenerative cell therapy in preclinical
models of PAH. As well, the literature will be assessed for study quality and risk of bias. The results will guide the design
of future clinical trials and preclinical animal studies.
Systematic review registration: CAMARADES (http://www.dcn.ed.ac.uk/camarades/SyRF/Protocols.htm).
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Background
Pulmonary hypertension is a progressive disease that
results from restricted blood flow through the pul-
monary circulation and loss of effective pulmonary
microvascular area. This leads to increased resistance
in the pulmonary vasculature and eventually right
heart failure [1]. Clinically, pulmonary arterial hyper-
tension (PAH) is defined by an increase in mean
pulmonary arterial pressure ≥25 mmHg at rest by
right heart catheterization with a pulmonary capillary
wedge pressure ≤15 mmHg. PAH, classified as World
Health Organization (WHO) Group I pulmonary
hypertension [1, 2], represents a group of diseases of
various etiologies that are characterized by increased
pulmonary vascular resistance due to pathology at the
level of the precapillary arteriolar system. Although
the mechanisms underlying the pathobiology of PAH
are still unclear, it is thought that injury to the
pulmonary endothelium leads to apoptosis which, in
turn, triggers processes that reduce the effective lung
vasculature, including widespread loss of functional
microcirculation and obliterative remodeling of the
small pulmonary arterioles due to the emergence of
growth dysregulated vascular cells [3]. Ultimately, loss
of lung microcirculation leads to progressive increase
in pulmonary vascular resistance, right ventricular
remodeling, and eventually right heart failure [4–6].
PAH is subdivided into subgroups based on etiology
such as idiopathic, hereditary, drug- and toxin-
induced, and PAH associated with other diseases such
as connective tissue disease HIV, schistosomiasis,
chronic hemolytic anemia, and congenital heart
disease (Table 1).
The current standard of care PAH-specific therapies
consists largely of pharmacological vasodilator agents,
such as phosphodiesterase-5 inhibitors, prostacyclin
analogs, and endothelin antagonists. These have only
modest effects on pulmonary hemodynamics, and
prognosis remains poor despite introduction of a num-
ber of new therapies in the last 5 years [7]. The most re-
cent estimate of 5-year survival of newly diagnosed PAH
is 61.2 % [7]. Thus, the development of clinically effect-
ive strategies to restore normal pulmonary structure and
function in established PAH are needed.
Recent understanding of the role of adult stem and
progenitor cells in the maintenance of vascular homeo-
stasis and repair of injury has stimulated interest in the
potential for regenerative cell therapies for PAH. Most
of the preclinical studies of cell therapy for PAH have
used two cell types in particular, early-outgrowth endo-
thelial progenitor cells (EPCs, also known as circulating
angiogenic cells, myeloid angiogenic cells) and mesen-
chymal stromal cells (MSCs, also known as mesenchy-
mal stem cells, adult stem cells) [8, 9]. EPCs and MSCs
have been described as dynamic and responsive cells
that can migrate to sites of vascular injury in several in
vivo animal disease models [10], facilitating neovasculari-
zation and reducing inflammation [8]. As a treatment for
PAH, preclinical studies involving these cell types have
demonstrated efficacy in improving key pathological
features of PAH such as cardiopulmonary hemodynamics,
restoring the degenerated microvascular area, and redu-
cing both right ventricular and pulmonary vascular re-
modeling [8]. A small number of clinical studies involving
stem/progenitor cell therapy on PAH patients have been
completed or are underway and show some promise in
controlling the extent of the disease [3, 11]. However, to
date, there has been no systematic synthesis of preclinical
studies investigating stem cells therapy for the treatment
of PAH.
In order to address this knowledge gap, we will
conduct a preclinical systematic review of regenerative
cell therapy for PAH. In contrast to narrative preclinical
reviews of stem cells for PAH treatment, this systematic
review will provide additional key evaluations. The
meta-analysis will provide an estimation of the cumula-
tive overall effect of stem cell treatment on pulmonary
hemodynamics based on currently available data in pre-
clinical studies. This systematic review will also attempt
to evaluate the quality of currently available evidence
based on risk of bias assessment and completeness of
reporting, and the potential for publication bias. This
data may impact the design of current preclinical testing
of stem cell therapies and potentially influence the
design of future clinical trials.
Table 1 Clinical classification of WHO group 1 pulmonary
hypertension




1.2.2 ALK-1, ENG, SMAD9, CAV1, KCNK3
1.2.3 Unknown
1.3 Drug- and toxin-induced
1.4 Associated with:
1.4.1 Connective tissue disease
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart disease
1.4.5 Schistosomiasis
1′ Pulmonary veno-occlusive disease and/or pulmonary capillary
hemangiomatosis
1″ Persistent pulmonary hypertension of the newborn (PPHN)
Adapted from Simonneau et al., JACC 2013 [1]
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Study questions
In preclinical studies of pulmonary arterial hypertension,
do PAH animals receiving regenerative cell therapy
exhibit improved pulmonary hemodynamics compared
to PAH animals not receiving regenerative cell therapy
and is regenerative cell therapy safe?
Methods/design
Protocol and registration
The protocol was developed by a research team of
clinical (DS, AZ) and preclinical research scientists (CS,
ML), experts in knowledge synthesis and translation (DF,
LM). The protocol will follow the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses Protocols
(PRISMA-P) checklist (Additional file 1: PRISMA check-
list). The protocol is registered through the Collaborative
Approach to Meta Analyses and Review of Animal Data
from Experimental Studies (CAMARADES) website
(http://www.camarades.info).
Types of studies
This review will include controlled studies (randomized,
pseudo-randomized and non-randomized) that evaluate
the efficacy or safety of regenerative cell therapy for
PAH.
Types of preclinical animal models
We will include preclinical in vivo models of PAH that
reproduce features of the pathophysiology associated
and/or etiology of human PAH [1]. Specifically, the eli-
gible animal models are the rodent monocrotaline
(MCT), chronic hypoxia (CH), and SU5416 + chronic
hypoxia (SU+CH) models. These are recognized as the
most representative and most widely utilized methods of
induction for modeling human PAH [12]. These models
do not require invasive surgery or extensive manipula-
tion that could be subject to technical variability and
therefore provide a predictable disease phenotype. These
models share in common the characteristic pathological
features of human PAH: endothelial dysfunction, SMC
proliferation, inflammation, and vascular narrowing and
rarefaction resulting in pulmonary hypertension and
right ventricular remodeling; however, only the SU+CH
model reproduces the complex obliterative vascular le-
sions that are typical of human PAH [13]. Mouse models
will not be considered for this systematic review as
currently available models (chronic hypoxia) lack signifi-
cantly elevated pulmonary pressures, right ventricular
hypertrophy, and pulmonary arteriolar remodeling [12].
Animal models of PH secondary to other causes such
as left heart disease, lung disease, or thromboembolism
(WHO Groups 3-5) [4] will not be included. Genetically
modified animals and will also be excluded. Since the
purpose of this study to inform future decisions for
designing clinical trials for adult populations, this study
will exclude neonatal animal models of pulmonary
hypertension.
Types of interventions
The intervention group will include animals receiving any
regenerative cell therapy (xenogeneic, syngeneic, or allo-
geneic cells from any tissue source). Experiments involv-
ing pretreatment of cells, co-treatment, and/or genetic
manipulation (e.g., engineered to over- or under-express
certain genes) will be classified as “cell modifications” for
subgroup analysis. Studies using non-stem/progenitor
cells (i.e., terminally differentiated cells such as mature
endothelial cells, smooth muscle cells, or fibroblasts) as
the therapeutic intervention will be excluded. Studies that
do not include the administration of viable cells, for
example, studies with only cell-free products derived from
stem/progenitor cells such as conditioned media, will also
be excluded.
Types of control comparisons
The preclinical comparison group will include animals
from studies that have had experimentally induced PAH
but have not been administered a regenerative cell
(vehicle control, control cell type, or no treatment).
Timing of outcome measurements
Outcomes will be assessed at least 1 week after interven-
tion to exclude the possibility of acute effects of cell
administration.
Preclinical primary endpoints
The current gold standard for the diagnosis and evaluation
of clinical pulmonary hypertension is direct pulmonary
hemodynamic measures by right heart catheterization. The
primary endpoint will be direct measures of pulmonary
hemodynamics (mean pulmonary arterial pressure, right
ventricular systolic pressure) measured after administration
of cells (Table 2). The primary outcome will be assessed at
the end of the follow-up period.
Preclinical secondary endpoints
We will collect data on all deaths and animal mortality.
Right ventricular (RV) remodeling is a forerunner of
right heart failure, which is characterized by decreased
function and dilatation of the RV and strongly correlates
with prognosis and survival in PH patients [14]. We will
collect morphometric data on right ventricular remodel-
ing expressed as the weight ratio of right ventricle/left
ventricle + septum. Other measures of cardiac function
and hemodynamics will also be collected to assess
functional performance of the heart such as cardiac
output and cardiac index (cardiac output/body weight)
and pulmonary vascular resistance.
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Table 2 Quantitative measures of severity of pulmonary hypertension
Collection method Parameter Surrogate index for Type of variable
Direct measurement Right ventricular systolic pressure (RVSP) Pulmonary hemodynamics [12, 30] Continuous
Mean pulmonary arterial pressure (mPAP) Pulmonary hemodynamics [12, 30] Continuous
Cardiac output, cardiac index Cardiac function [12, 30] Continuous (calculated)
Pulmonary vascular resistance (PVR) Pulmonary hemodynamics Continuous (calculated)
Post-mortem tissue collection Morphometric RV hypertrophy (RV/LV+S) RV remodeling [12, 30] Continuous
Echocardiography Pulmonary artery acceleration time (PAT) Pulmonary hemodynamics [12, 30] Continuous
RV free wall thickness RV remodeling [12, 30] Continuous
Tricuspid annular plane systolic excursion (TAPSE) Cardiac function Continuous
Ratio of deaths/total participants
at experimental endpoint
Death Mortality Continuous
Survival time relative to induction Survival Survival Continuous
Table 3 SYRCLE risk of bias (RoB) tool
Item Type of bias Domain Description of domain Review authors’ judgment
1 Selection bias Sequence
generation
Describe the methods used, if any, to generate
the allocation sequence in sufficient detail to
allow an assessment whether it should produce
comparable groups.
Was the allocation sequence adequately
generated and applied?a
2 Selection bias Baseline
characteristics
Describe all the possible prognostic factors or
animal characteristics, if any, that are compared
in order to judge whether or not intervention
and control groups were similar at the start of
the experiment.
Were the groups similar at baseline or were
they adjusted for confounders in the analysis?
3 Selection bias Allocation
concealment
Describe the method used to conceal the
allocation sequence in sufficient detail to
determine whether intervention allocations
could have been foreseen before or during
enrolment.
Was the allocation adequately concealed?a
4 Performance bias Random housing Describe all measures used, if any, to house the
animals randomly within the animal room.
Were the animals randomly housed during the
experiment?
5 Performance bias Blinding Describe all measures used, if any, to blind trial
caregivers and researchers from knowing which
intervention each animal received. Provide any
information relating to whether the intended
blinding was effective.
Were the caregivers and/or investigators
blinded from knowledge which intervention
each animal received during the experiment?
6 Detection bias Random outcome
assessment
Describe whether or not animals were selected at
random for outcome assessment, and which
methods to select the animals, if any, were used.
Were animals selected at random for outcome
assessment?
7 Detection bias Blinding Describe all measures used, if any, to blind
outcome assessors from knowing which
intervention each animal received. Provide any
information relating to whether the intended
blinding was effective.
Was the outcome assessor blinded?
8 Attrition bias Incomplete
outcome data
Describe the completeness of outcome data for
each main outcome, including attrition and
exclusions from the analysis. State whether
attrition and exclusions were reported, the
numbers in each intervention group (compared
with total randomized animals), reasons for
attrition or exclusions, and any re-inclusions in
analyses for the review.
Were incomplete outcome data adequately
addressed?a
9 Reporting bias Selective outcome
reporting
State how selective outcome reporting was
examined and what was found.
Are reports of the study free of selective
outcome reporting?a
10 Other Other sources of
bias
State any important concerns about bias not
covered by other domains in the tool.
Was the study apparently free of other
problems that could result in high risk of bias?a
aItems in agreement with the items in the Cochrane Risk of Bias tool. Hooijmans et al. BMC Medical Research Methodology 2014 14:43 doi:10.1186/1471-2288-14-43
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We will collect data from other noninvasive measures
obtained by echocardiography to evaluate cardiac struc-
ture and pulmonary hemodynamics (Table 2). Mortality
and survival will also be collected to evaluate the safety
of the intervention.
Electronic search methods for study identification
In consultation with the review team, electronic search
strategies will be developed for each database by an
experienced medical information specialist. Ovid
MEDLINE®, Ovid MEDLINE® In-Process & Other Non-
Indexed Citations, and EMBASE Classic + EMBASE will
be searched. The strategy appended was used to search
in MEDLINE (Additional file 2). The search strategy will
be validated using the Peer Review of Electronic Search
Strategies (PRESS) template by another information
specialist [15].
Search strategies will use a combination of controlled
vocabulary (for example stem cells, pulmonary hyperten-
sion) and keywords (for example, EPC, MSC, iPSC,
HSC, PAH), and parsing will be formatted accordingly
to each database. We will use modified animal filters
from previously published methods [16, 17] validated for
PubMed/MEDLINE and EMBASE. There will be no date
restrictions on any of the searches. In addition, a manual
review of the bibliographies of selected articles and
relevant reviews will be performed. Only articles in the
English language will be included in the review.
Study selection
Titles and abstracts of search results will be screened
independently by two individuals. Full text of all
potentially eligible studies will be reviewed based on our
eligibility criteria. Disagreements between reviewers will
be resolved by consensus or by a third member of the
systematic review team (DJS). Reasons for exclusion of
potentially eligible studies will be recorded in accord-
ance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines
developed for proper reporting of clinical systematic
reviews [18].
Data collection and process and data items
Data will be extracted independently by two individuals
into standardized, electronic pilot-tested forms using
DistillerSR software (https://distillercer.com). Specific
data elements collected for this review are listed in
Table 2.
Assessment of risk of bias
Risk of bias will be assessed independently in duplicate
for each included study using the Systematic Review
Centre for Laboratory animal Experimentation (SYR-
CLE) risk of bias tool. The SYRCLE tool was adapted
from the Cochrane Risk of Bias Tool to assess the
methodological quality using criteria specific to animal
studies (Table 3). Items in this tool include assessments
for selection bias (sequence generation, baseline cha-
racteristics, allocation concealment), performance bias
(random housing, blinding), detection bias (random out-
come assessment, blinded outcome assessment), attrition
bias (completeness of outcome data), and reporting bias.
For each included study, each parameter for type of bias
will be scored as low, high, or unclear risk of bias.
Assessment of external validity
This review will record features that will facilitate judg-
ments of external validity. External validity in preclinical
research concerns the extent to which results can be
generalized to different experimental measures, settings,
and times [19]. These assessments aid in the ability to
replicate experimental findings. External validity will be
assessed by subgroup analysis of the primary outcome
based on: age, gender, species and strain of animal,
model of PAH, severity of PAH, use of cell preservation,
tissue source of regenerative cell product, timing of cell
administration, dose of cells, type of control, presence of
cell modification, and number of participating study
centers (Table 4). These data will help evaluate the effect
of factors such as animal characteristics and regenerative
Table 4 Elements of external validity
Category Specific items
Strain e.g., Sprague-Dawley versus
Fischer 344
Species Rat, mouse, dog, pig, etc.
Age Age in weeks, body weight
Gender Male versus female versus mix of
genders used
Model of PAH MCT, CH, or SUHx
Severity of PAH RVSP or mPAP in control group
Cell preservation Fresh versus fresh from previously
cryopreserved versus thawed
cryopreserved product
Tissue source of regenerative
cell product
Bone marrow versus peripheral
blood versus cord blood
Timing of cell administration
following induction of PAH
Early (<2 weeks) versus late
(≥2 weeks) intervention
Follow-up duration Primary outcome assessed at 1, 2, 3,
and 4+ weeks after intervention
Route of cell administration Intravenous versus intratracheal versus
intraperitoneal versus intramuscular
Dose of cells e.g., 1 × 106 cells
Type of control PBS versus normal saline versus
fibroblasts versus heat-killed cells
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cell preparation. As well, this will help identify optimal
conditions for regenerative cell therapy to inform future
clinical trials.
Assessment of construct validity
Construct validity in preclinical research refers to the
ability of a study to generalizable to a clinical scenario
[20]. Threats to construct validity arise when experimental
conditions (model, intervention, outcomes) are not repre-
sentative of the clinical scenario.
We will assess construct validity based on a pre-
defined checklist of factors aimed evaluate how closely
the study resembles clinical PAH. The domains assessed
will be animal subjects, outcome measures, modeling of
disease, administration of intervention, and environment
(Table 5). These will be recorded as yes/no answers.
Description of reporting
We will apply the Animal Research: Reporting of In vivo
Experiments (ARRIVE) guidelines to evaluate the quality
Table 5 Elements of construct validity
Grouping Recommendations from guidelinesa Specific application to PAH Justification
Animal subjects Model matches age of patients to
clinical setting
Adult animals included Typical onset of PAH occurs in
adulthood [31, 32]
Characterization of animal properties
at baseline
RVSP or mPAP assessed at baseline Confirmation that the model
successfully establishes PAH
Matching model to sex of patients in
clinical setting
Both male and female animal
included
Prevalence of PAH occurs in female
versus males is 2:1 [31, 32]
Outcome
measurements
Matching of measure to clinical
outcome
Clinically relevant outcome reported
(e.g., pulmonary hemodynamics, RV
remodeling, cardiac function,
mortality)
Clinically relevant outcomes may
increase potential generalizability to
clinical setting
Long-term follow-up (>3 weeks
post-intervention)
PAH is a chronic disease; long-term




Right heart catheterization is the
gold standard for diagnosing PAH
Assessment of multiple manifestations
of disease phenotype






Efficacy in multiple manifestations of




Matching model to human
manifestation
Criteria for PAH are met in disease
control (mPAP >25 mmHg;
RVSP >35 mmHg [12, 33])




A molecular or cellular mechanism
of treatment is measured and
reported
Ensures therapy is producing a
biological effect; ensures negative




Matching timing of treatment
delivery to clinical setting
Intervention is given after PAH is
established (>2 weeks in animal
models)
PAH usually present with symptoms
before diagnosis
Matching the duration/exposure of
treatment to clinical setting
Evidence of cell persistence in any
animal organ
Ensures presence of cells during
course of treatment
Matching model to co-interventions
in clinical setting
Animals are on background medical
therapy for PAH (e.g., Prostacyclins
endothelin receptor antagonists,
PDE5 inhibitors, calcium channel
blockers)
PAH patients would be on
conventional pharmacotherapy
Environment Address confounders associated with
setting, experimental setting
General anesthetic is not used
during outcome measurements
Anesthetics may exert effects on
cardiovascular system; patients
undergo right heart catheterization
under local anesthetic,
echocardiography performed
without anesthetics in patients
aRecommendations to reduce threats to construct validity were identified by [20]
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of reporting in preclinical studies. The ARRIVE guidelines
were developed by the National Centre for the Replace-
ment, Refinement, and Reduction of Animals in Research
(NC3Rs) to improve the transparent and comprehensive
reporting of research methods and results for in vivo
animal experiments [21].
Data analysis
Continuous endpoints will be pooled using the ratio of
weighted means using the inverse variance random
effects method [22, 23]. Death will be analyzed as the
mortality ratio of ndeaths/ntotal at defined endpoints and
by mean survival in days. Statistical heterogeneity of
included studies will be measured using the I2 test with
95 % confidence intervals [24]. An evaluation for the
presence of publication bias will be conducted with fun-
nel plots and Egger’s regression test [25].
Planned subgroup analyses will be examined on the
primary endpoint of right heart catheterization
hemodynamics (RVSP/mPAP). Heterogeneity will be
analyzed for the following: PAH induction method, age,
sex, strain, regenerative cell type, tissue origin of cells, tim-
ing of administration (<2 weeks post-induction, ≥2 weeks
post-induction), follow-up period (0, 1, 2, 3, 4+ weeks
post-intervention), route of delivery, cell dose, dose
frequency, use of cell pretreatments and other
enhancement strategies (e.g., gene transfection), and
sample sizes of study.
Discussion
The timing of this review is highly relevant, as clinical tri-
als have been completed (NCT00257413, NCT00641836,
NCT00469027) [11, 3 ,26]. So far, based on limited short-
term data, the results of completed clinical trials have
shown relatively modest benefits [11] compared to the ef-
fect sizes reported in some preclinical literature [27, 28].
Most of the evidence supporting regenerative cell therapy
for PAH has been based on findings observed in preven-
tion studies rather than treatment studies in established
pulmonary hypertension [8], which may have contributed
to the overestimation of the degree of their efficacy.
Therefore, a thorough examination of the study design
with attention to the timing of interventions and suitabil-
ity of follow-up duration must be conducted to determine
the validity of the available evidence and potential for clin-
ical translation.
Systematic reviews should be valuable in stem cell
research because of the high degree of heterogeneity of
cell products used for therapy. As such, a secondary aim
of this study will be to evaluate the relative efficacy be-
tween regenerative cell types. Although EPCs and MSCs
have both been studied extensively in preclinical models,
we anticipate that other cell products such as cells de-
rived from embryonic stem cells or induced pluripotent
stem cell may also have in vivo efficacy. Still, guidelines
and/or criteria for what constitutes a particular regen-
erative cell type are ill-defined and when available, they
are loosely defined based on an evolving understanding
of stem cell biology [29]. In the absence of such stan-
dards, this review will address the level of transpar-
ency in reporting of pertinent information regarding
stem cell isolation and culture techniques and quality
control for each cell type, as well as the delivery and
dosing methods.
We anticipate that this comprehensive synthesis will
provide valuable information in translating stem cell
therapy to the clinic. In addition, this review will have
an immediate impact on preclinical research by
highlighting knowledge gaps and areas to improve study
design for future preclinical investigations of PAH.
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